Stratz T, Müller W
Hochrhein-Institut, Rheumaklinik, Bad Säckingen, Germany.
Scand J Rheumatol Suppl. 2000;113:66-71. doi: 10.1080/030097400446689.
In a pilot study, the action of the 5-HT3 receptor antagonist, tropisetron, on different types of local rheumatic pain and inflammatory effects was studied. With intra-articular injection of tropisetron, an improvement in inflammation and pain was obtained in inflammatory rheumatic diseases and activated osteoarthrosis. Also, the majority of patients with localized soft-tissue rheumatic diseases (periarthritis) demonstrated an obvious decrease in their pain following local infiltration of tropisetron. Chronic low back pain and cervical pain responded somewhat to i.v. treatment with tropisetron. The effect of the 5-HT3 receptor antagonists is probable primarily to limit the release of substance P, which acts as a pain and inflammatory mediator, and is itself released by the neurogenic inflammation that occurs after the binding of serotonin to its corresponding receptor. These results should be backed up with placebo controlled studies, which if confirmed, might imply that 5-HT3 receptor antagonists could supplement or replace the local administration of corticosteroids.
在一项初步研究中，对5-羟色胺3（5-HT3）受体拮抗剂托烷司琼对不同类型的局部风湿性疼痛及炎症效应的作用进行了研究。通过关节内注射托烷司琼，在炎性风湿性疾病和活动性骨关节炎中炎症和疼痛均得到改善。此外，大多数局限性软组织风湿性疾病（肩周炎）患者在局部注射托烷司琼后疼痛明显减轻。慢性腰痛和颈痛对托烷司琼静脉治疗有一定反应。5-HT3受体拮抗剂的作用可能主要是限制P物质的释放，P物质作为一种疼痛和炎症介质，其本身是在血清素与其相应受体结合后发生的神经源性炎症释放出来的。这些结果应以安慰剂对照研究加以佐证，若得到证实，则可能意味着5-HT3受体拮抗剂可补充或替代皮质类固醇的局部给药。
